Physician profile
Ryan C Jackson
NPI 1407318223
$494.11
in general payments reported to CMS, 2019-2025
11 companies · $480 in 2025
The $480 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $14.46 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168.82 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $78.11 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $76.74 | 2025 | Entyvio, Gattex |
| Ardelyx, INC. | $32.15 | 2025 | Ibsrela |
| Qol Medical, LLC | $31.41 | 2025 | Sucraid |
| Conmed Corporation | $27.06 | 2025 | Conmed Generators |
| Janssen Biotech, INC. | $18.96 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.01 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $15.24 | 2025 | Clenpiq |
| Celgene Corporation | $14.46 | 2024 | Zeposia |
| Vivus LLC | $14.15 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.